Immune thrombocytopenia
Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …
[HTML][HTML] Thrombopoietin receptor agonists: ten years later
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …
Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia
DJ Kuter, M Efraim, J Mayer, M Trněný… - … England Journal of …, 2022 - Mass Medical Soc
Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …
may increase platelet counts in patients with immune thrombocytopenia by means of dual …
Recent advances in the mechanisms and treatment of immune thrombocytopenia
Primary immune thrombocytopenia is an autoimmune disease associated with a reduced
peripheral blood platelet count. The phenotype is variable with some patients suffering no …
peripheral blood platelet count. The phenotype is variable with some patients suffering no …
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo‐controlled trials
J Bussel, DM Arnold, E Grossbard… - American journal of …, 2018 - Wiley Online Library
Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated
platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk …
platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk …
An update on the pathophysiology of immune thrombocytopenia
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder mediated by
antiplatelet autoantibodies and antigen-specific T cells that either destroy platelets …
antiplatelet autoantibodies and antigen-specific T cells that either destroy platelets …
Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment
O Miltiadous, M Hou, JB Bussel - Blood, The Journal of the …, 2020 - ashpublications.org
Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …
[HTML][HTML] Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors
P von Hundelshausen, R Lorenz… - Thrombosis and …, 2021 - thieme-connect.com
A series of cases with rare thromboembolic incidents including cerebral sinus vein
thrombosis (some of them fatal) and concomitant thrombocytopenia occurring shortly after …
thrombosis (some of them fatal) and concomitant thrombocytopenia occurring shortly after …
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
AC Newland, B Sánchez‐González… - American journal of …, 2020 - Wiley Online Library
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder,
characterized by a low platelet count (< 100× 109/L) in the absence of other causes …
characterized by a low platelet count (< 100× 109/L) in the absence of other causes …
Platelet activation mechanisms and consequences of immune thrombocytopenia
Autoimmune disorders are often associated with low platelet count or thrombocytopenia. In
immune-induced thrombocytopenia (IIT), a common mechanism is increased platelet …
immune-induced thrombocytopenia (IIT), a common mechanism is increased platelet …